Tanox Story
Dr. Nancy T. Chang 唐南珊 博士
President/CEO and Chairman of BOD, Tanox Biosystems, Inc.
摘要：
Tanox, Inc. is engaged in the discovery and development of therapeutic products that beneficially influence or are derived from the immune system. Tanox is focusing its product development efforts on therapeutics in three broad areas: immunology (asthma/allergy and autoimmune diseases), infectious diseases and oncology. Tanox currently has products under development in several areas. Anti-IgE monoclonal antibody, E25, is in clinical development for the treatment of allergic rhinitis and allergic asthma. For treatment of AIDS, Tanox has developed a panel of anti-HIV monoclonal antibodies that target different major neutralizing sites on HIV. To complement its HIV program, Tanox recently licensed a novel antibody that targets the cellular receptor for HIV, CD4. This antibody has shown the ability to reduce HIV in a primate infectivity model. Tanox plans to develop the anti-CD4 antibody alone or in combination with one of the anti-HIV antibodies.
The research strategy at Tanox is straightforward: understand the biology of the disease; identify a key factor responsible for that biology; and generate an effective drug targeting that key component. The development strategy of Tanox is to select one to three of its product opportunities and retain development control over these for the U.S. and European markets. For its remaining product opportunities, Tanox will seek alliances to provide the necessary development and commercialization support. The new facility of Tanox includes a 1500L bioreactor for large scale process development and production of animal cell culture derived products and is available to both Tanox and other companies for production of monoclonal antibodies and other biologic products for large scale clinical trials and initial market launch.
簡歷：
Dr. Chang is a co-founder of Tanox Biosystems, serving as its president and Chairman of the Board since March 1986, and assuming the position of CEO in June, 1990. Piror to the organization of this progressive biotech company, Dr. Chang served as Research Associate Professor at Baylor College of Medicine in the Department of Virology and Epidemiology and continued until 1991 as an Adjunct Associate Professor. She held several research positions of increasing significance at Centocor, Inc. Prior to Centocor, she was involved in the development of interferons at Hoffman la Roche. Dr. Chang has published over 40 articles and is an inventor of seven U.S. patents and has other patents pending. In 1993, she was elected Entrepreneur of Year for the Houston Region in the area of High Technology/Life Sciences and in 1992 received the award for Outstanding Achievement in BioMedical Technology and Business Development: American Association of Chinese Professionals.